Developer docs
API playgroundTry for free, no card

Search company profiles

Rapt

Full company profile

uuid000cdwx

Namestring
Rapt
Legal namestring
RAPT Therapeutics, Inc.
Websiteurl
rapt.com
Company typeenum
Public
Founded yearint
2021
Descriptiontext

Rapt is a privately-held media monetization solutions provider founded in 1998 and headquartered in San Francisco, California. According to its firmographic profile, the company delivers technology and strategic advisory services to media companies, with a headcount of 51–100 employees. The combination of a technology product and adjacent consulting layer positions Rapt as a hybrid platform/services vendor in the ad-tech and media revenue optimization stack.

The company has raised disclosed funding across four documented rounds between 2002 and 2013, totaling roughly $23.6 million. Capital sources include a mix of established early-stage venture firms — Accel, Levensohn Venture Partners, Summit Partners, and Octane Capital Management — plus the global/emerging-markets-focused investor 500 Global in its most recent 2013 round. The investor profile is consistent with a company that scaled through the early internet/ad-tech era and maintained VC conviction across multiple cycles, though the absence of any recorded capital or product activity after 2013 limits visibility into current growth posture.

Detailed product architecture, pricing, customer segmentation, revenue model, and go-to-market mechanics are not documented in the available input. Specific technology components, competitive positioning, named customers, and channel strategy are not disclosed; analysis is therefore grounded in firmographic, capital, and headcount evidence only.

Short descriptiontext

Rapt is a San Francisco-based media monetization solutions and strategic advisory provider serving media companies, founded in 1998 with a 51–100 employee headcount and venture-backed history through 2013.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersOlympia, United States
HQ citystring
Olympia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
anti-IgE antibody, monoclonal antibody therapy, food allergy treatment, chronic urticaria therapy, biopharmaceutical drug development
Industry1 code
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical-stage biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Clinical Trials
TypeOne Time License
Description

RAPT Therapeutics was a clinical-stage biopharmaceutical company developing oral therapies for oncology and inflammatory diseases. The company had drug candidates in clinical trials. The primary exit strategy was through acquisition, as evidenced by the GSK acquisition completed on March 3, 2026 at $58 per share.

finance.yahoo.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

RAPT Therapeutics is a clinical-stage biopharmaceutical company developing ozureprubart, a novel half-life extended anti-IgE monoclonal antibody designed to treat IgE-mediated food allergy and chronic spontaneous urticaria. The candidate is engineered for extended pharmacokinetics that may enable dosing every 8 to 12 weeks, compared to every 2 to 4 weeks for the first-generation anti-IgE therapy omalizumab, and is being advanced through Phase 2 clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Extended dosing interval of 8-12 weeks vs 2-4 weeks for omalizumab
+3 more records
Product overview1 text field

RAPT Therapeutics is a clinical-stage biopharmaceutical company with a single-product focus on developing ozureprubart, a long-acting anti-IgE monoclonal antibody. The company is advancing this lead product candidate through Phase 2 clinical trials for food allergy and chronic spontaneous urticaria. Ozureprubart is designed to offer improved dosing convenience (every 8-12 weeks) over existing anti-IgE therapies and potential eligibility for patients with high IgE or body weight who cannot be treated with current options.

Product and service1 record
1Ozureprubart (RPT904 / JYB1904)
CategoryAnti-IgE monoclonal antibody therapeutic candidate
Description

A novel half-life extended monoclonal antibody designed to bind free human IgE, a key driver of allergic diseases. It is being developed as a treatment for IgE-mediated food allergy (peanut, milk, egg, cashew, walnut) and chronic spontaneous urticaria, with potential dosing every 8 to 12 weeks compared to every 2 to 4 weeks for omalizumab (Xolair). Ozureprubart is an investigational agent and is not approved by any regulatory agency as a treatment for any indication.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Co-developers and co-marketers of Xolair (omalizumab), the first and only approved anti-IgE monoclonal antibody. Directly comparable therapeutic target (IgE), same indications (CSU, food allergy), and the established standard-of-care that ozureprubart is designed to improve upon.

TypeBroad incumbent
Description

Co-marketers of Dupixent (dupilumab), a leading IL-4/IL-13 inhibitor for atopic dermatitis, asthma, CRSwNP, and EoE. Competes for the same allergy/inflammation patient population and prescriber relationships that ozureprubart targets in food allergy and CSU.

TypeBroad incumbent
Description

Markets Tezspire (tezepelumab) and Fasenra (benralizumab) for severe asthma and related type-2 inflammatory conditions. Operates in overlapping immunology indications and competes for biologic-eligible patients in allergy practices.

TypeBroad incumbent
Description

Develops Ayvakit (avapritinib) for systemic mastocytosis and is expanding into broader allergic/inflammatory diseases with KIT and mast-cell targets. Comparable small-cap clinical-to-commercial immunology player with adjacent allergy indications.

5Allakos
TypeEmerging player
Description

Clinical-stage biotech developing antibodies targeting mast cells and eosinophils for allergic and inflammatory diseases, including chronic spontaneous urticaria. Directly competes for CSU patients and addresses overlapping IgE/mast cell biology.

TypeEmerging player
Description

Commercial-stage dermatology biotech with Zoryve (roflumilast) for atopic dermatitis and seborrheic dermatitis. Operates in adjacent inflammatory skin and allergy indications and targets overlapping specialist prescriber base (allergists, dermatologists).

TypeEmerging player
Description

Developer of neffy, an intranasal epinephrine spray approved for emergency treatment of allergic reactions including food anaphylaxis. Operates in the same food allergy patient population and is now commercializing a complementary acute-care product.

TypeEmerging player
Description

Clinical-stage biotech developing MRGPRX2 and MRGPRX4 antagonists for chronic itch, urticaria, and mast cell-mediated diseases. Directly competes in chronic urticaria (CSU) with novel mechanisms targeting mast cell pathways downstream of IgE activation.

TypeEmerging player
Description

Clinical-stage immunology biotech developing barzolvolimab (anti-KIT mAb) for chronic urticaria and other mast cell-driven diseases. Competes head-to-head in CSU and adjacent inflammatory indications with a biologic in advanced-stage development.

TypeEmerging player
Description

Clinical-stage biotech developing novel immunomodulators for inflammatory skin diseases including atopic dermatitis and chronic pruritus. Comparable small-cap clinical-stage company addressing type-2 inflammation biology with mAb and small molecule approaches.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Rapt

Clinical-stage biopharmaceuticalsrapt.com

Rapt is a San Francisco-based media monetization solutions and strategic advisory provider serving media companies, founded in 1998 with a 51–100 employee headcount and venture-backed history through 2013.

What Rapt does

Rapt is a privately-held media monetization solutions provider founded in 1998 and headquartered in San Francisco, California. According to its firmographic profile, the company delivers technology and strategic advisory services to media companies, with a headcount of 51–100 employees. The combination of a technology product and adjacent consulting layer positions Rapt as a hybrid platform/services vendor in the ad-tech and media revenue optimization stack.

The company has raised disclosed funding across four documented rounds between 2002 and 2013, totaling roughly $23.6 million. Capital sources include a mix of established early-stage venture firms — Accel, Levensohn Venture Partners, Summit Partners, and Octane Capital Management — plus the global/emerging-markets-focused investor 500 Global in its most recent 2013 round. The investor profile is consistent with a company that scaled through the early internet/ad-tech era and maintained VC conviction across multiple cycles, though the absence of any recorded capital or product activity after 2013 limits visibility into current growth posture.

Detailed product architecture, pricing, customer segmentation, revenue model, and go-to-market mechanics are not documented in the available input. Specific technology components, competitive positioning, named customers, and channel strategy are not disclosed; analysis is therefore grounded in firmographic, capital, and headcount evidence only.

Rapt firmographics

Firmographics
Name
Rapt
Legal name
RAPT Therapeutics, Inc.
Website
https://rapt.com
Company type
Public
Founded year
2021
Operating status
Acquired
Headcount range
51–100 employees
Short description
Rapt is a San Francisco-based media monetization solutions and strategic advisory provider serving media companies, founded in 1998 with a 51–100 employee headcount and venture-backed history through 2013.
Ownership category
akta.pro rank

Rapt industry classification

Industry
Product category
Clinical-stage biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Anti-IgE antibody
  • Monoclonal antibody therapy
  • Food allergy treatment
  • Chronic urticaria therapy
  • Biopharmaceutical drug development

Where Rapt is headquartered

Location

Headquarters

HQ city
Olympia
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Rapt business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Others

Revenue model

  1. Drug Development and Clinical Trials: RAPT Therapeutics was a clinical-stage biopharmaceutical company developing oral therapies for oncology and inflammatory diseases. The company had drug candidates in clinical trials. The primary exit strategy was through acquisition, as evidenced by the GSK acquisition completed on March 3, 2026 at $58 per share.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Rapt product offering

Product offering

Core offering

RAPT Therapeutics is a clinical-stage biopharmaceutical company developing ozureprubart, a novel half-life extended anti-IgE monoclonal antibody designed to treat IgE-mediated food allergy and chronic spontaneous urticaria. The candidate is engineered for extended pharmacokinetics that may enable dosing every 8 to 12 weeks, compared to every 2 to 4 weeks for the first-generation anti-IgE therapy omalizumab, and is being advanced through Phase 2 clinical trials.

Product overview

RAPT Therapeutics is a clinical-stage biopharmaceutical company with a single-product focus on developing ozureprubart, a long-acting anti-IgE monoclonal antibody. The company is advancing this lead product candidate through Phase 2 clinical trials for food allergy and chronic spontaneous urticaria. Ozureprubart is designed to offer improved dosing convenience (every 8-12 weeks) over existing anti-IgE therapies and potential eligibility for patients with high IgE or body weight who cannot be treated with current options.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ozureprubart (RPT904 / JYB1904) A novel half-life extended monoclonal antibody designed to bind free human IgE, a key driver of allergic diseases. It is being developed as a treatment for IgE-mediated food allergy (peanut, milk, egg, cashew, walnut) and chronic spontaneous urticaria, with potential dosing every 8 to 12 weeks compared to every 2 to 4 weeks for omalizumab (Xolair). Ozureprubart is an investigational agent and is not approved by any regulatory agency as a treatment for any indication.

Quantifiable outcome

  • Extended dosing interval of 8-12 weeks vs 2-4 weeks for omalizumab
  • +3 more outcomes

Companies that use Rapt

Customer profile

Segments2 records

Ideal customer profiles2 records

Rapt technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Rapt partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights2 records

Rapt competitors and assessment

Company assessment

Broad incumbents

  • Genentech (Roche) / Novartis: Co-developers and co-marketers of Xolair (omalizumab), the first and only approved anti-IgE monoclonal antibody. Directly comparable therapeutic target (IgE), same indications (CSU, food allergy), and the established standard-of-care that ozureprubart is designed to improve upon.
  • Sanofi / Regeneron: Co-marketers of Dupixent (dupilumab), a leading IL-4/IL-13 inhibitor for atopic dermatitis, asthma, CRSwNP, and EoE. Competes for the same allergy/inflammation patient population and prescriber relationships that ozureprubart targets in food allergy and CSU.
  • AstraZeneca: Markets Tezspire (tezepelumab) and Fasenra (benralizumab) for severe asthma and related type-2 inflammatory conditions. Operates in overlapping immunology indications and competes for biologic-eligible patients in allergy practices.
  • Blueprint Medicines: Develops Ayvakit (avapritinib) for systemic mastocytosis and is expanding into broader allergic/inflammatory diseases with KIT and mast-cell targets. Comparable small-cap clinical-to-commercial immunology player with adjacent allergy indications.

Emerging players

  • Allakos: Clinical-stage biotech developing antibodies targeting mast cells and eosinophils for allergic and inflammatory diseases, including chronic spontaneous urticaria. Directly competes for CSU patients and addresses overlapping IgE/mast cell biology.
  • Arcutis Biotherapeutics: Commercial-stage dermatology biotech with Zoryve (roflumilast) for atopic dermatitis and seborrheic dermatitis. Operates in adjacent inflammatory skin and allergy indications and targets overlapping specialist prescriber base (allergists, dermatologists).
  • ARS Pharmaceuticals: Developer of neffy, an intranasal epinephrine spray approved for emergency treatment of allergic reactions including food anaphylaxis. Operates in the same food allergy patient population and is now commercializing a complementary acute-care product.
  • Escient Pharmaceuticals: Clinical-stage biotech developing MRGPRX2 and MRGPRX4 antagonists for chronic itch, urticaria, and mast cell-mediated diseases. Directly competes in chronic urticaria (CSU) with novel mechanisms targeting mast cell pathways downstream of IgE activation.
  • Celldex Therapeutics: Clinical-stage immunology biotech developing barzolvolimab (anti-KIT mAb) for chronic urticaria and other mast cell-driven diseases. Competes head-to-head in CSU and adjacent inflammatory indications with a biologic in advanced-stage development.
  • Evommune: Clinical-stage biotech developing novel immunomodulators for inflammatory skin diseases including atopic dermatitis and chronic pruritus. Comparable small-cap clinical-stage company addressing type-2 inflammation biology with mAb and small molecule approaches.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights7 records

Customer concentration

Rapt social profiles

Digital presence

Rapt financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Rapt leadership team

Management profile

Number of profiles

Rapt funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Rapt M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rapt

What does Rapt do?

RAPT Therapeutics is a clinical-stage biopharmaceutical company developing ozureprubart, a novel half-life extended anti-IgE monoclonal antibody designed to treat IgE-mediated food allergy and chronic spontaneous urticaria. The candidate is engineered for extended pharmacokinetics that may enable dosing every 8 to 12 weeks, compared to every 2 to 4 weeks for the first-generation anti-IgE therapy omalizumab, and is being advanced through Phase 2 clinical trials.

Is Rapt a public or private company?

Rapt is a public company. It is classified as corporate owned and is currently acquired.

When was Rapt founded?

Rapt was founded in 2021. It employs 51 to 100 people.

Where is Rapt based?

Rapt is headquartered in Olympia, United States, in the North America region.

How does Rapt make money?

One revenue line is on record: drug Development and Clinical Trials.

Who are Rapt's main competitors?

Broad incumbents on record are Genentech (Roche) / Novartis, Sanofi / Regeneron, AstraZeneca and Blueprint Medicines. Emerging players are Allakos, Arcutis Biotherapeutics, ARS Pharmaceuticals, Escient Pharmaceuticals, Celldex Therapeutics and Evommune.

Does Rapt have an API?

No public API is recorded for Rapt.

What industry is Rapt in?

Rapt's product category is Clinical-stage biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MorningstarTIME Turns to Kana's Agentic AI to Power the Next Era of Ad Sales and Campaign DeliveryTIME deployed Kana's agentic marketing applications, compressing proposal turnaround from days to minutes and automating campaign monitoring. The rollout marks a shift to treating agentic AI as core infrastructure for sales and operations.AsiaeA Look at Big Pharma's Shopping List: Selective Focus on Next-Gen ADCs and ImmunologyGlobal biopharma M&A deals exceeded 50 in the first half of this year, a significant increase from approximately 30 deals in the same period last year, reflecting a targeted investment strategy to fill future revenue gaps ahead of patent cliffs. Major transactions include AbbVie's USD 10.9 billion acquisition of Apogee Therapeutics, GSK's USD 10.6 billion purchase of Nuvallent and USD 2.2 billion acquisition of RAPT, Vertex's USD 10 billion deal for Crinetics, and Novartis' acquisition of Myricx Bio for up to USD 1.5 billion. By company, Eli Lilly led with USD 23.3 billion across nine deals, followed by Gilead at approximately USD 15 billion and GSK at USD 13.8 billion, with activity concentrated in immunology, rare diseases, and ADC technologies.SpringerLinkRAPT: AI–Powered IoT Framework for Real-Time Respiratory Disorders Monitoring and PredictionThe article discusses the development of RAPT, an AI-powered IoT framework designed for real-time respiratory disorder monitoring using wearable devices and telemedicine. It leverages deep learning to analyze respiratory sounds and patient data, supporting remote healthcare and assisted living solutions.YahooThis Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per ShareOrbiMed Advisors disclosed a purchase of 556,273 shares of RAPT Therapeutics on February 17, 2026, valued at approximately $17.28 million, building a total position worth $55.64 million representing 1.1% of the fund's 13F reportable assets under management. Less than three weeks after the quarter ended, RAPT Therapeutics was acquired by GSK for $58 per share, representing a 75% premium over the stock's December 31 closing price of $33.15. The acquisition highlights how large pharmaceutical companies value promising immunology assets, particularly RAPT's anti-IgE antibody candidate ozorepubart targeting severe allergic reactions.PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RAPT Therapeutics, Inc. - RAPTPomerantz LLP is investigating RAPT Therapeutics for potential securities fraud, advising investors to contact the firm. The investigation follows a March 14, 2023 press release stating a Phase 2b trial delay, which caused RAPT's stock to fall 20.24% to $19.70.BioWorldWall Street en-Raptured as oral AD drug makes it look EASI in phase IbRapt Therapeutics reported promising phase Ib data for its oral AD drug RPT-193, which blocks CCR4 to inhibit Th2 cell migration. The stock surged 115.5% to $40.02, though CEO Brian Wong said more learning is needed.PR NewswireRAPT Touch and OEM Partner to Demonstrate RAPT's Latest Technology Designed for Windows Ink and the Education Market, at BETT 2018RAPT Touch will demonstrate its Windows Ink-enabled interactive flat panels at BETT 2018, showcasing Microsoft OneNote and Whiteboard on a 75-inch panel. The company will also announce a new education-focused program, with up to 20 simultaneous fine-tip stylii and 7ms tracking latency.TechCrunchMicrosoft Stands Firm on Yahoo Bid As It Reports Flat Revenues And A Big Drop In Operating IncomeMicrosoft reported flat Q2 revenues of $14.5 billion and operating income fell 33% to $4.4 billion. CFO Chris Liddell said the company will not raise its Yahoo bid, citing Yahoo's declining search share and profitability. He said Microsoft will reconsider alternatives if no agreement is reached by the weekend.TechCrunchMicrosoft Picks Up Another Ad Startup: RaptMicrosoft acquired Rapt, a web-based yield-management software for publishers, with the price undisclosed. Rapt, used by CNET, Dow Jones, and The New York Times, will be rolled into the Atlas Publisher Suite within the aQuantive business. The deal follows Microsoft's Yahoo merger pursuit and the Google-DoubleClick acquisition.